Article

Preclinical evaluation of CDK4 phosphorylation predicts high sensitivity of malignant pleural mesotheliomas to CDK4/6 inhibition

2022-04-11

Abstract excerpt

Malignant pleural mesothelioma (MPM) is an aggressive cancer with limited therapeutic options. In this study, we evaluated the impact of CDK4/6 inhibition by palbociclib in a panel of 28 MPM cell lines, including 19 patient-derived cell lines, using a variety of approaches including RNA-sequencing. Palbociclib used alone sufficed to strongly and durably inhibit the proliferation of 23 MPM cell lines, indicating a...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 1cf849a0-e20d-5d23-913a-1165231fa87c
DOI: 10.1101/2022.04.11.487857

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Preclinical evaluation of CDK4 phosphorylation predicts high sensitivity of malignant pleural mesotheliomas to CDK4/6 inhibitionDOI 10.1101/2022.04.11.487857Read

Efficacy of CDK4/6 inhibitors in preclinical models of malignant pleural mesotheliomaSemantic proximity Read

Inhibition of CDK4/6 Overcomes Primary Resistance to PD-1 Blockade in Malignant MesotheliomaSemantic proximity Read

Efficacy of CDK4 inhibition against sarcomas depends on their levels of CDK4 and p16ink4 mRNASemantic proximity Read

microRNA-497-5p-based screening identifies a novel synthetic lethal-type interaction via PKMYT1 and WEE1 in pleural mesotheliomaSemantic proximity Read

CDK4/6 inhibition stabilizes disease in patients with p16-null non-small cell lung cancer and is synergistic with mTOR inhibitionSemantic proximity Read

Isolated <i>BAP1</i> loss in malignant pleural mesothelioma predicts immunogenicity with implications for immunotherapeutic responseSemantic proximity Read

Molecular Changes in Mesothelioma With an Impact on Prognosis and TreatmentSemantic proximity Read

CDK4 phosphorylation status and rational use for combining CDK4/6 and BRAF/MEK inhibition in advanced thyroid carcinomasSemantic proximity Read

Isolated BAP1 Genomic Alteration in Malignant Pleural Mesothelioma Predicts Distinct Immunogenicity with Implications for Immunotherapeutic ResponseSemantic proximity Read

The Cell-Cycle Regulator CDK4: An Emerging Therapeutic Target in MelanomaSemantic proximity Read

Integrated genomics identify novel immunotherapy targets for malignant mesotheliomaSemantic proximity Read

Immune Microenvironment and Genetics in Malignant Pleural MesotheliomaSemantic proximity Read